Classification of cancer chemotherapeutic drugs according to their ability to potentiate contact sensitivity to dinitrofluorobenzene

The anticancer chemotherapeutic drugs cyclophosphamide (CY), melphalan (L-phenylalanine mustard; L-PAM), 5-fluorouracil (5-FU), methotrexate (MTX), and daunorubicin (DAU) were tested for ability to potentiate contact sensitization (CS) to dinitrofluorobenzene (DNFB) in mice and to inhibit induction...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 6; no. 6; p. 1341
Main Authors Ben-Efraim, S, Gal, T, Zimber, C, Weiss, D W
Format Journal Article
LanguageEnglish
Published Greece 01.11.1986
Subjects
Animals
Antineoplastic Agents - classification
Antineoplastic Agents - pharmacology
Cyclophosphamide - pharmacology
Daunorubicin - pharmacology
Dermatitis, Contact - etiology
Dinitrofluorobenzene - analogs & derivatives
Dinitrofluorobenzene - pharmacology
Drug Synergism
Melphalan - pharmacology
Methotrexate - pharmacology
Mice
Mice, Inbred BALB C
Nitrobenzenes - pharmacology
T-Lymphocytes - drug effects
Online AccessGet more information

Cover

More Information
Summary:The anticancer chemotherapeutic drugs cyclophosphamide (CY), melphalan (L-phenylalanine mustard; L-PAM), 5-fluorouracil (5-FU), methotrexate (MTX), and daunorubicin (DAU) were tested for ability to potentiate contact sensitization (CS) to dinitrofluorobenzene (DNFB) in mice and to inhibit induction of unresponsiveness to such sensitization by preceding exposure to dinitrobenzenesulfonate (DNBS). Administration of CY and L-PAM but not of 5-FU, MTX, and DAU, after DNBS treatment (and before DNFB sensitization) reduced the degree of unresponsiveness effected by DNBS. It is suggested that the test system of CS might be utilized for screening the ability of cancer chemotherapeutic agents to act as nonspecific immuno-modulators.
ISSN:0250-7005